Cancer screening guidelines can feel like a maze. Recommendations come from multiple organizations — the US Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), the National Comprehensive Cancer Network (NCCN) — and they don’t always agree. The start age for breast cancer mammography changed in 2024. The start age for colorectal cancer screening changed in 2018 and again in 2021. Prostate cancer screening remains genuinely controversial. Some cancers have no recommended screening at all.
This guide covers current US cancer screening guidelines for the most common and screenable cancers — breast, cervical, colorectal, lung, prostate, and skin — organized by who needs what test, at what age, and how often.
The Guideline Landscape — Who Issues Cancer Screening Recommendations?
US Preventive Services Task Force (USPSTF)
The USPSTF is a federally appointed panel of primary care and prevention experts that assigns letter grades to preventive health services:
- Grade A or B: Strong or moderate recommendation — under the Affordable Care Act (ACA), most health insurance plans must cover Grade A and B services without cost-sharing (no copayment, no deductible)
- Grade C: Individualized decision-making recommended
- Grade D: Recommend against
- Grade I: Insufficient evidence
The ACA cost-free coverage rule is financially significant. Breast, cervical, colorectal, and lung cancer screening tests with USPSTF Grade A/B recommendations can typically be received at no out-of-pocket cost by eligible patients on compliant insurance plans.
The USPSTF is the most conservative of the three bodies. It weighs harms — false positives, over-diagnosis, biopsy complications, unnecessary treatment — seriously against benefits.
American Cancer Society (ACS)
ACS publishes patient-facing guidelines that tend to start screening earlier and allow more frequent testing than USPSTF. ACS prioritizes not missing cancers and offers more options in some areas (e.g., annual mammography for more age groups).
National Comprehensive Cancer Network (NCCN)
NCCN is a consortium of major cancer centers publishing detailed clinical guidelines. NCCN is most valuable for high-risk individuals — those with hereditary syndromes, strong family histories, or prior cancer — where it provides more granular risk-stratified recommendations.
Breast Cancer Screening
Average Risk
| Organization | Start Age | Test & Interval | Stop Age |
|---|---|---|---|
| USPSTF 2024 Grade B | 40 | Mammography every 2 years | 74 (insufficient evidence 75+) |
| ACS 2015 | 40–44 (optional) / 45 (recommended) | Annual age 45–54; biennial or annual 55+ | Continue with ≥10 yr life expectancy |
The USPSTF 2024 update lowered the recommended start age from 50 to 40. This change was driven by updated modeling showing benefits from earlier mammography — particularly for Black women, who have higher rates of early-onset breast cancer and a higher risk of aggressive tumors before age 50.
Dense Breast Tissue
Approximately 40–50% of women who undergo mammography have dense breast tissue (BI-RADS categories C or D). Dense tissue reduces mammography sensitivity — both dense tissue and tumors appear white on mammograms, making tumors harder to detect. Several states have breast density notification laws requiring radiologists to inform patients.
Supplemental screening options for dense breasts include breast MRI (recommended for those with sufficient elevated risk) and ultrasound. USPSTF 2024 acknowledged dense breasts as an important issue but did not recommend supplemental screening for all women with dense breasts.
High Risk
Women with a ≥20% lifetime risk — including BRCA1/2 carriers, those with strong family history, or prior chest radiation before age 30 — should discuss enhanced screening with a genetic counselor or clinician.
- BRCA1 carriers: Annual breast MRI starting age 25 + annual mammography
- BRCA2 carriers: Annual breast MRI starting age 25–30 + annual mammography
- The two tests detect different tumor types; both are needed, not either/or
Cervical Cancer Screening
Virtually all cervical cancers are caused by persistent high-risk HPV infection. The preferred test now detects the virus itself (primary HPV testing), not only its cellular effects (Pap smear).
| Age Group | ACS 2020 (Preferred) | USPSTF 2018 (Acceptable) |
|---|---|---|
| Under 21 | No screening — regardless of sexual activity | |
| 21–24 | No screening (ACS starts at 25) | Pap every 3 years (USPSTF starts at 21) |
| 25–65 | Primary HPV test every 5 yrs (preferred); or co-test q5y; or Pap q3y | Pap every 3 yrs; or HPV every 5 yrs (30+); or co-test q5y (30+) |
| 65+ | Discontinue if adequate prior screening history | |
Colorectal Cancer Screening
Why the Start Age Dropped to 45
Colorectal cancer incidence in adults under 50 increased approximately 51% from 1994 to 2014 (Siegel et al., 2020, CA: A Cancer Journal for Clinicians). This trend drove the ACS to lower its screening start age from 50 to 45 in 2018; USPSTF followed in 2021 (Grade B).
Test Options for Average-Risk Adults Starting at Age 45
| Test | Frequency | Key Points |
|---|---|---|
| Annual FIT | Every year | At-home stool test; non-invasive; positive FIT requires colonoscopy |
| Stool DNA (Cologuard) | Every 1–3 years | FIT + DNA markers; higher sensitivity; higher false positive rate; positive requires colonoscopy |
| Colonoscopy | Every 10 years | Gold standard; polyps removed during procedure; requires bowel prep + sedation; perforation risk ~1–3/1,000 |
| CT colonography | Every 5 years | No sedation; polyps ≥6mm trigger colonoscopy; not covered by all insurers |
High Risk
- First-degree relative with CRC before age 60: Colonoscopy starting at 40 or 10 years before the relative’s diagnosis (whichever is earlier), every 5 years
- Lynch syndrome: Colonoscopy every 1–2 years starting age 20–25
- Familial adenomatous polyposis (FAP): Annual sigmoidoscopy from age 10–12; prophylactic colectomy often recommended
Lung Cancer Screening
Lung cancer kills more Americans than any other cancer. The NLST trial (2011, NEJM) established that annual LDCT in high-risk smokers reduces lung cancer mortality by 20%. The European NELSON trial (2020, NEJM) confirmed this, showing a 24% reduction in men and 33% in women.
Who Qualifies (USPSTF 2021 / ACS 2023 — Grade B)
- Age 50–80
- 20 or more pack-years of smoking history (packs/day × years smoked)
- Currently smoking OR quit within the past 15 years
Approximately 25% of LDCT scans detect a pulmonary nodule — the vast majority are benign. Radiologists use the Lung-RADS system to classify nodules and determine follow-up:
- Lung-RADS 1–2 (negative/benign): Annual screening continues as scheduled
- Lung-RADS 3 (probably benign): Repeat CT in 6 months
- Lung-RADS 4A/4B (suspicious): PET/CT, additional imaging, or biopsy depending on findings
Lung cancer screening must be accompanied by smoking cessation counseling. LDCT is a complement to quitting — not a substitute for it.
Prostate Cancer Screening (PSA Testing)
Prostate cancer screening is uniquely controversial. The PSA blood test can detect prostate cancer earlier than clinical symptoms — but cannot distinguish well between indolent cancers that may never cause harm and aggressive ones that will. The resulting over-diagnosis and over-treatment (surgery and radiation with significant risks of incontinence and erectile dysfunction) is a genuine harm that must be weighed against benefits.
Current Recommendations
| Organization | Recommendation | Grade / Notes |
|---|---|---|
| USPSTF 2018 | Ages 55–69: Shared decision-making only. Age 70+: Recommend against. | Grade C (55–69) / Grade D (70+) |
| ACS 2023 | Discuss at 50 (avg risk); age 45 (Black men + FDR before 65); age 40 (multiple FDRs) | Discussion, not automatic testing |
For men diagnosed with low-risk prostate cancer, active surveillance — monitoring with regular PSA, digital rectal exams, and periodic biopsies without immediate treatment — is now the standard of care. Many men on active surveillance will never require treatment. This approach exists because the side effects of treating low-risk prostate cancer are real and sometimes severe.
Skin Cancer Screening
The USPSTF (2023) concluded there is insufficient evidence (Grade I) to recommend for or against routine skin cancer screening in average-risk adults. This is not a recommendation against screening; it reflects the absence of RCT evidence showing that routine clinician skin exams reduce skin cancer mortality.
Regular skin self-examination using the ABCDE rule is broadly endorsed — and any skin lesion that is new, growing, or meets ABCDE criteria should be evaluated promptly by a dermatologist.
Annual full-body skin exam by a dermatologist is recommended for individuals with:
- Personal history of melanoma or squamous cell carcinoma
- Multiple or atypical (dysplastic) moles
- Strong family history of melanoma
- Significant cumulative sun exposure or prior radiation to the skin
- Immunosuppression (organ transplant recipients have substantially elevated skin cancer risk)
Cancers Without Established Population Screening
| Cancer | USPSTF | Why |
|---|---|---|
| Pancreatic | Grade D (recommend against for average risk) | No accurate screening test; potential harms outweigh benefits |
| Ovarian | Grade D (recommend against ultrasound + CA-125) | High false positive rate → unnecessary surgeries; no mortality benefit in trials |
| Bladder | No recommendation | Insufficient evidence for average-risk adults |
| Thyroid | Grade D (recommend against) | High over-diagnosis of clinically insignificant cancers |
| Oral | Grade I (insufficient evidence) | Dental exams often include opportunistic oral cancer check |
Key Principles for Screening Conversations
- Life expectancy matters. Screening benefits take years to materialize. Most guidelines include ≥10 years life expectancy as a prerequisite. For older adults with significant comorbidities, the harm-benefit calculation shifts.
- The best test is the one you’ll actually do. Annual FIT done consistently protects more than a colonoscopy that never gets scheduled.
- Positive screens require follow-up. Screening is not complete until abnormal results have been worked up. Be proactive about receiving results and understanding next steps.
- Shared decision-making is required for some tests. For PSA and LDCT, the guidelines explicitly call for a conversation about benefits and harms before testing. The conversation IS part of the screening process.
- Know your family history. First-degree family history of cancer is one of the most important modifiers of when to start screening, how often, and which tests apply. Bring a family history summary to your preventive care visit.
Frequently Asked Questions
At what age should I start getting screened for cancer?
It depends on the cancer type and your individual risk. For most average-risk adults: mammography (breast) from age 40; colonoscopy or annual FIT (colorectal) from age 45; HPV testing (cervical) from age 25; PSA discussion (prostate) at age 50 for average risk (earlier for Black men and those with family history); LDCT (lung) from age 50 with 20+ pack-years and currently smoking or quit within 15 years. Family history and genetic risk factors can move start ages earlier. Talk to your primary care provider about your individual schedule.
Which cancer screening tests does insurance have to cover?
Under the ACA, most health insurance plans must cover USPSTF Grade A and B preventive services without cost-sharing. This currently includes: mammography (Grade B), cervical cancer screening (Grade A), colorectal cancer screening (Grade B), and LDCT for qualifying lung cancer screening (Grade B). PSA testing is Grade C and does not trigger mandatory cost-free coverage. Coverage details vary by plan — verify with your insurer and confirm whether the test is being ordered as “screening” (preventive) vs. “diagnostic” (for symptoms), as this affects how it is billed.
What is the difference between annual FIT and colonoscopy for colorectal cancer screening?
FIT is a simple at-home stool test that detects blood in the stool; it’s non-invasive and done annually. A positive FIT always requires follow-up colonoscopy. Colonoscopy directly visualizes the entire colon and allows removal of polyps during the procedure; it’s done every 10 years when no polyps are found and requires bowel preparation and sedation. Annual FIT completed consistently is an equally acceptable, evidence-based alternative to colonoscopy. The most important factor is whichever option you will reliably complete.
I smoke — should I get a CT scan for lung cancer?
If you meet all three criteria — age 50–80, 20+ pack-years, and currently smoking or having quit within 15 years — annual LDCT is a USPSTF Grade B recommendation covered by most insurance plans without cost-sharing. Talk to your doctor. If you smoke but don’t yet meet the age criteria, this is a strong reason to prioritize quitting — smoking cessation substantially reduces cancer risk, and LDCT is a complement to quitting, not a substitute.
Should I get a PSA test for prostate cancer?
This depends on your age, race, family history, and your preferences about the trade-offs involved. USPSTF recommends a shared decision-making conversation for men aged 55–69, and recommends against PSA for men 70+. ACS recommends discussing PSA at age 50 for average-risk men, age 45 for Black men and those with a first-degree relative with prostate cancer before age 65. The key is an informed conversation about both potential benefits and potential harms before testing — because an elevated PSA can lead to anxiety, additional tests, biopsy, and treatment of cancers that might never have caused symptoms.
At what age can I stop getting cancer screening?
There is no universal stopping age — guidelines are clearer about when to start than when to stop. For mammography: USPSTF gives insufficient evidence for ages 75+; ACS recommends continuing with ≥10 years life expectancy. For colonoscopy: most guidelines suggest stopping around 75–85 depending on individual health. For cervical screening: stop at 65 with adequate prior screening history. For PSA: USPSTF recommends against testing at 70+. The decision to stop should be individualized based on overall health, life expectancy, and the time horizon needed for screening benefit to materialize.
What does it mean if my screening test comes back positive?
A positive screening result does NOT mean you have cancer — screening tests have false positive rates. A positive result means additional evaluation is needed. For mammography, a callback typically leads to diagnostic imaging; only a small fraction of callbacks result in biopsy, and of biopsies, only a fraction are cancerous. For FIT, a positive requires colonoscopy. For LDCT, most nodules found are benign. Follow up promptly on any positive result, ask specifically what the next steps are, and keep track of when you receive the outcome of that follow-up evaluation.
- US Preventive Services Task Force. Breast Cancer Screening (2024); Cervical Cancer Screening (2018); Colorectal Cancer Screening (2021); Lung Cancer Screening (2021); Prostate Cancer Screening (2018); Skin Cancer Prevention (2023).
- American Cancer Society. Breast (2015); Cervical (2020); Colorectal (2018); Lung (2023); Prostate Cancer Early Detection (2023).
- NCCN Clinical Practice Guidelines — Breast, CRC, Lung, Prostate, Genetic/Familial High-Risk Assessment, 2024.
- Siegel RL, Miller KD, Goding Sauer A, et al. (2020). Colorectal cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(3), 145–164.
- NLST Research Team (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine, 365(5), 395–409.
- de Koning HJ, van der Aalst CM, de Jong PA, et al. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine, 382(6), 503–513.